Lannett Sees Boost From Adderall Shortages And Pricing Reprieve

Firm Also Makes ANDA Deals And Gets FDA Nod For Seymour Plant

In a busy period for Lannett, the company has benefited from a US shortage of generic Adderall rivals as well as a “more favorable pricing environment” to enjoy better results than expected – albeit with sales still significantly down on last year.

Empty blister pack drug shortages
Lannett has benefited from stepping in during a shortage • Source: Shutterstock

Stepping in to supply the market during US shortages of generic Adderall (mixed amphetamine salts), combined with a “more favorable pricing environment” for US generics, have helped to boost Lannett in its financial first quarter ended 30 September, allowing the firm to generate what it described as “better than expected financial results.”

Nevertheless, Lannett’s sales still slid by more than a quarter to $75.1m and the company reported an operating loss of...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Earnings

More from Business